Merck (MRK) earnings Q2 2024

Merck lowered its adjusted profit guidance to a range of $7.94 and $8.04 per share, from a previous forecast of $8.53 to 8.65 per share. That updated outlook reflects one-time charges of 26 cents and 51 cents per share for the company’s acquisitions of Harpoon Therapeutics and EyeBio, respectively, Merck said.

Here’s what Merck reported for the second quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

• Earnings per share: $2.28 adjusted vs. $2.15 expected
• Revenue: $16.11 billion vs. $15.84 billion expected

The drugmaker posted a net income of $5.46 billion, or $2.14 per share, for the second quarter. That compares with a net loss of $5.98 billion, or $2.35 per share, during the year-earlier period, which included a charge related to its acquisition of Prometheus Biosciences.

Excluding acquisition and restructuring costs, Merck earned $2.28 per share for the three-month period.

Merck reported $16.11 billion in revenue for the quarter, up 7% from the same period a year ago. 

The results come as Merck prepares to offset losses from Keytruda’s patent expiration in 2028 with a handful of new deals under its belt and key drug launches. 

That includes Winrevair, a medication approved in the U.S. in March to treat a progressive and life-threatening lung condition. Some analysts expect that worldwide sales of Winrevair could reach $5 billion by 2030. 

It also includes Capvaxive, a vaccine designed to protect adults from a bacteria known as pneumococcus that can cause serious illnesses and lung infection. The shot was approved in the U.S. last month. 

Merck’s pharmaceutical division booked $14.41 billion in revenue during the second quarter, up 7% from the same period a year ago. The unit develops a wide range of drugs for a range of disease areas. 

The company’s immunotherapy Keytruda recorded $7.27 billion in revenue during the quarter, up 16% from the year-earlier period. Analysts had been expecting $7.12 billion in Keytruda sales, according to estimates from StreetAccount. 

Sales of Gardasil, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., were nearly flat. 

Gardasil brought in $2.48 billion in sales, up just 1% from the second quarter of 2023. Merck said that growth was driven by higher prices in the U.S. but hampered by lower sales in China due to shipment timing. 

The segment results were slightly below the $2.51 billion that analysts expected, according to StreetAccount. 

Winrevair posted $70 million in revenue for the second quarter following its approval in March. Analysts had expected the treatment to book $59.4 million in sales. 

Meanwhile, the company’s Type 2 diabetes treatment Januvia saw $629 million in sales, down 27% from the same period a year ago. Merck said the decline was primarily due to lower demand and prices of the drug, along with generic competition in several countries. 

Januvia is one of 10 drugs targeted in ongoing Medicare drug price negotiations, a policy that aims to make costly medications more affordable for seniors. Those price talks, a key provision of President Joe Biden’s Inflation Reduction Act, will end at the beginning of August.

Sales of Merck’s Covid antiviral pill, Lagevrio, also fell, down 46% to $110 million during the quarter. Still, that topped analysts’ expectations of $81.5 million in sales, according to StreetAccount.  

Merck’s animal health division, which develops vaccines and medicines for dogs, cats and cattle, posted $1.48 billion in sales for the second quarter. That is up 2% from the year-earlier period and slightly below what analysts surveyed by StreetAccount were expecting.